Welcome to our dedicated page for ProMIS Neurosciences Common Shares (ON) news (Ticker: PMN), a resource for investors and traders seeking the latest updates and insights on ProMIS Neurosciences Common Shares (ON) stock.
ProMIS Neurosciences Inc. (Nasdaq: PMN) is a clinical-stage biotechnology company dedicated to discovering and developing precision therapeutics and companion diagnostics for neurodegenerative diseases such as Alzheimer’s Disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). Leveraging its proprietary target discovery engine, ProMIS™ and Collective Coordinates, the company aims to predict novel targets on misfolded proteins, known as Disease Specific Epitopes (DSEs), to create highly selective antibody therapeutics.
ProMIS Neurosciences is advancing its lead product, PMN310, a humanized IgG1 antibody designed to selectively target toxic amyloid-beta oligomers, believed to be a major driver of AD. PMN310's distinctive approach potentially improves efficacy and reduces the risk of amyloid-related imaging abnormalities (ARIA), a common side effect in other amyloid-beta-directed therapies. The product is currently in Phase 1a clinical trials, with initial safety and pharmacokinetic data expected by mid-2024.
In addition to Alzheimer's disease, ProMIS is developing PMN267, a humanized IgG1 antibody targeting misfolded TDP-43 proteins in ALS. Preclinical data have shown that PMN267 helps mitigate neurodegeneration by targeting the pathogenic interaction between TDP-43 and SOD1 in ALS.
ProMIS is also focusing on therapeutic targets for multiple synucleinopathies, including Parkinson’s disease, dementia with Lewy bodies, and MSA. The company's pipeline includes a computationally-derived amyloid-beta vaccine for AD and multiple earlier-stage antibody candidates for other neurodegenerative conditions.
Recent achievements include the publication of preclinical data supporting PMN267 as a potential ALS treatment in the Journal of Biological Chemistry and the identification of RACK1 as a novel target for ALS and frontotemporal lobar degeneration (FTLD). The company has also secured key U.S. and international patents to protect its intellectual property, particularly around PMN310, which further validates its innovative approach to treating neurodegenerative diseases.
With offices in Toronto, Ontario, and Cambridge, Massachusetts, ProMIS Neurosciences continues to build on its robust scientific foundation focused on tackling diseases characterized by abnormal, misfolded proteins. The company aims to advance clinical development across its therapeutic pipeline while maintaining a tight control on cash management, ensuring the sustainability of its operations and long-term growth.
ProMIS Neurosciences (TSX: PMN, Nasdaq: PMN) recently showcased preclinical data supporting its Aβ vaccine candidate aimed at preventing Alzheimer’s disease (AD) progression. The findings were presented at the AAN 2023 Annual Meeting, highlighting the vaccine’s potential advantages over traditional antibody treatments, including sustained efficacy, fewer required doses, and reduced risks of inflammatory responses. The computationally designed vaccine targets misfolded Aβ oligomers—key drivers of AD—showing promising immune responses in mouse models. No adverse T helper responses were observed, and the vaccine selectively activated antibodies against toxic oligomers, potentially minimizing risks associated with plaque-binding antibodies. ProMIS’s focus remains on developing an effective AD vaccine to combat neurodegenerative diseases.
ProMIS Neurosciences Inc. (TSX: PMN; Nasdaq: PMN) announced the submission of an Investigational New Drug (IND) application to the FDA for PMN310, targeting Alzheimer’s disease (AD). This is a significant milestone in advancing PMN310 towards clinical trials, offering potential new treatment options for AD patients. PMN310 selectively targets toxic oligomers of amyloid-beta, a key factor in AD pathology, showing strong binding to these harmful proteins in preclinical studies. The company anticipates transitioning to a clinical-stage entity pending regulatory approval. Management emphasizes the antibody's potential for a differentiated safety profile compared to existing treatments, which often bind to non-targeted plaques, potentially minimizing associated risks.
ProMIS Neurosciences (TSX: PMN) has announced promising results for its lead candidate, PMN310, which targets toxic oligomers linked to Alzheimer’s disease (AD). In a recent presentation at the AD/PD 2023 conference, new preclinical data showed PMN310 selectively binds to these harmful oligomers, differentiating it from other amyloid-beta-directed antibodies. This selectivity may reduce the risk of side effects commonly associated with plaque-binding therapies. ProMIS plans to submit an IND application in the coming weeks for clinical development of PMN310, aiming to advance its treatment options for patients suffering from AD.
FAQ
What is the current stock price of ProMIS Neurosciences Common Shares (ON) (PMN)?
What is the market cap of ProMIS Neurosciences Common Shares (ON) (PMN)?
What is ProMIS Neurosciences Inc.?
What is PMN310?
What diseases does ProMIS Neurosciences focus on?
How does ProMIS Neurosciences discover new therapeutic targets?
What recent achievements has ProMIS Neurosciences made?
Where are ProMIS Neurosciences' offices located?
What is the status of PMN310's clinical trials?
What is PMN267?
What is the significance of amyloid-related imaging abnormalities (ARIA)?
What kind of intellectual property protection does ProMIS Neurosciences have?
